S&P Capital IQ commences Standard & Poor's Factual Stock Report coverage on Epigenomics AG

Sep 7 2013

S&P Capital IQ announced today that it has commenced Standard & Poor's Factual Stock Report coverage on cAG.

Epigenomics AG (OTC: EPGNY; FSE: ECX) is a molecular diagnostics company focusing on developing and commercializing of in vitro diagnostic (IVD) tests for the screening and diagnosis of cancer. The company's products are based on a technology platform, which relies on a fundamental biological phenomenon called DNA methylation as a source for the discovery of highly informative and disease-specific biomarkers which are at the core of every diagnostic test it has developed so far.

Epigenomics develops and commercializes diagnostic tests in colorectal cancer (CRC) and in lung cancer; both via direct marketing and sales efforts of IVD kits and through non-exclusive licensing partnerships for the biomarkers constituting the basis for these products. The company directly addresses certain market segments with its own products, while others are or will be served by partners through the licenses granted to them.

The company's lead product is Epi proColon^®, a blood-based test for the early detection of CRC which relies on its DNA methylation biomarker, Septin9. The majority of Epigenomics' activities are focused on the introduction of Epi proColon^® as an IVD kit in the United States, the world's largest commercial market for molecular diagnostic products. In 2012, the company completed the Premarket Approval (PMA) application and is expecting an approval decision from the U.S. Food and Drug Administration (FDA) before the end of 2013. Blood-based tests using the Septin9 biomarker are available worldwide through the company's partners, including Abbott Molecular Diagnostics, Inc., Quest Diagnostics, Inc., ARUP Laboratories, Inc., Gamma Dynacare, and Companion Dx Reference Lab. The product and diagnostic service offerings are performed on the basis of licenses granted to these partners by Epigenomics.

In July 2013, Epigenomics announced findings from a health economic study done at Stanford University School of Medicine. According to the study, Septin9 testing provided potential for saving lives while being health economically beneficial as an attractive screening alternative to established methods for a population that would otherwise be non-compliant to CRC screening.

On March 7, 2013, Epigenomics announced that it signed a licensing agreement with BioChain for Septin9 in China.

Standard & Poor's Factual Stock Report coverage on Epigenomics AG will also be accessible on an ongoing basis to the investment community by scores of buy-side institutions and sell-side firms that utilize S&P Capital IQ research and information platforms daily. Millions of self-directed investors also have access to the report via their e-brokerage accounts. Please visit http://www.epigenomics.com/de for additional information.